Why the study?
Does anticoagulation reduce cardiovascular events in patients with device-detected atrial fibrillation with or without vascular disease?
Population
6,546 patients with device-detected atrial fibrillation with or without vascular disease from the NOAH-AFNET…
Comparison
Anticoagulation (edoxaban or apixaban) vs No anticoagulation
Design
Meta-analysis
Key result
Anticoagulation in patients with device-detected atrial fibrillation showed a trend toward greater cardiovascular benefit in those with vascular disease compared to those without (p-interaction=0.08).
Authors
Loading...
Anticoagulation may reduce events more in DDAF with vascular disease than without; extends risk stratification for shared decisions in device-detected AF.
Meta-Analysis (n=6,546)
Randomized
Yes
Does anticoagulation reduce cardiovascular events in patients with device-detected atrial fibrillation with or without vascular disease?
p-value: p=0.08
Patients with device-detected atrial fibrillation and concomitant vascular disease may derive a greater benefit from anticoagulation compared to those without vascular disease, despite a similar relative increase in major bleeding.
Schnabel et al. (2024) conducted a meta-analysis in Device-detected atrial fibrillation (n=6,546). Anticoagulation vs. No anticoagulation was evaluated on Composite of stroke, systemic arterial embolism, myocardial infarction, pulmonary embolism or cardiovascular death (p=0.08). Anticoagulation in patients with device-detected atrial fibrillation showed a trend toward greater cardiovascular benefit in those with vascular disease compared to those without (p-interaction=0.08).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: